EP1608395A4 - Antikrebsmittel mit lk8-protein als wirkstoff - Google Patents

Antikrebsmittel mit lk8-protein als wirkstoff

Info

Publication number
EP1608395A4
EP1608395A4 EP04713257A EP04713257A EP1608395A4 EP 1608395 A4 EP1608395 A4 EP 1608395A4 EP 04713257 A EP04713257 A EP 04713257A EP 04713257 A EP04713257 A EP 04713257A EP 1608395 A4 EP1608395 A4 EP 1608395A4
Authority
EP
European Patent Office
Prior art keywords
protein
active ingredient
anticancer agent
anticancer
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04713257A
Other languages
English (en)
French (fr)
Other versions
EP1608395A1 (de
Inventor
Hyunkyung Yu
Jang-Seong Kim
Jin-Hyung Ahn
Ho-Jeong Lee
Kwan-Yub Kang
Hyung-Kwon Lim
In-Hwan Lim
Sung Geun Kim
Hak Kyu Joo
Jihyun Lee
Yeup Yoon
Doo-Hong Park
Jung Hwan Park
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mogam Biotechnology Research Institute
Original Assignee
Mogam Biotechnology Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mogam Biotechnology Research Institute filed Critical Mogam Biotechnology Research Institute
Publication of EP1608395A1 publication Critical patent/EP1608395A1/de
Publication of EP1608395A4 publication Critical patent/EP1608395A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
EP04713257A 2003-02-20 2004-02-20 Antikrebsmittel mit lk8-protein als wirkstoff Withdrawn EP1608395A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR2003010797 2003-02-20
KR1020030010797A KR100595364B1 (ko) 2003-02-20 2003-02-20 Ｌｋ8 단백질을 유효성분으로 포함하는 항암제
PCT/KR2004/000357 WO2004073730A1 (en) 2003-02-20 2004-02-20 Anticancer agent comprising lk8 protein as an active ingredient

Publications (2)

Publication Number Publication Date
EP1608395A1 EP1608395A1 (de) 2005-12-28
EP1608395A4 true EP1608395A4 (de) 2007-10-31

Family

ID=36116045

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04713257A Withdrawn EP1608395A4 (de) 2003-02-20 2004-02-20 Antikrebsmittel mit lk8-protein als wirkstoff

Country Status (9)

Country Link
EP (1) EP1608395A4 (de)
JP (1) JP2006518342A (de)
KR (1) KR100595364B1 (de)
CN (1) CN100546646C (de)
AU (1) AU2004212856B2 (de)
BR (1) BRPI0407611A (de)
CA (1) CA2516172A1 (de)
RU (1) RU2306147C2 (de)
WO (1) WO2004073730A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7285277B2 (en) 2002-03-15 2007-10-23 Mogam Biotechnology Research Institute Anticancer agent
KR20050090420A (ko) 2002-12-26 2005-09-13 다케다 야쿠힌 고교 가부시키가이샤 메타스틴 유도체 및 이의 용도
JP4660486B2 (ja) * 2004-01-09 2011-03-30 モガム バイオテクノロジー リサーチ インスティチュート ヒトアポリポ蛋白質（ａ）クリングルＬＫ６８またはＬＫ８遺伝子を有効成分として含有する抗癌治療剤及びそれを使用した癌治療方法
SG153865A1 (en) 2004-06-25 2009-07-29 Takeda Pharmaceutical Metastin derivatives and use thereof
TWI386417B (zh) 2005-12-22 2013-02-21 Takeda Pharmaceutical 轉移抑素衍生物及其用途
US8404643B2 (en) 2005-12-22 2013-03-26 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
TWI404726B (zh) 2006-10-25 2013-08-11 Takeda Pharmaceutical 腫瘤轉移抑制素衍生物及其用途
KR100888022B1 (ko) * 2006-12-21 2009-03-09 재단법인 목암생명공학연구소 면역글로불린 Ｆｃ와 인간 아포리포단백질（ａ）크링글절편의 융합단백질 ＬＫ8­Ｆｃ
FR2919062B1 (fr) 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage de l'aminoacylase 1 pour le diagnostic in vitro du cancer colorectal.
FR2919060B1 (fr) 2007-07-19 2012-11-30 Biomerieux Sa Procede de dosage de l'ezrine pour le diagnostic in vitro du cancer colorectal.
FR2919061B1 (fr) 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage de la plastine-i pour le diagnostic in vitro du cancer colorectal.
JP5715817B2 (ja) 2007-07-19 2015-05-13 ビオメリューＢｉｏｍｅｒｉｅｕｘ 結腸直腸癌のインビトロ診断のための肝臓脂肪酸結合タンパク質、ｃｅａおよびｃａ１９−９のアッセイのための方法
FR2919065B1 (fr) 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage de l'apolipoproteine ai pour le diagnostic in vitro du cancer colorectal
FR2919064B1 (fr) 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage de l'apolipoproteine all pour le diagnostic in vitro du cancer colorectal
FR2919063B1 (fr) 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage du leucocyte elastase inhibitor pour le diagnostic in vitro du cancer colorectal.
FR2933773B1 (fr) 2008-07-10 2013-02-15 Biomerieux Sa Procede de dosage de la proteine disulfide isomerase pour le diagnostic in vitro du cancer colorectal
WO2012067427A2 (ko) * 2010-11-16 2012-05-24 재단법인 목암생명공학연구소 Lk8 단백질을 유효성분으로 포함하는 당뇨망막병증 또는 노인성 황반변성의 예방 또는 치료용 약학 조성물

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3725473B2 (ja) * 1999-09-15 2005-12-14 モーガン バイオテクノロジー リサーチ インスティテュート 新規血管形成阻害剤

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
KIM J-S ET AL: "Human apolipoprotein(a) kringle V inhibits angiogenesis in vitro and in vivo by interfering with the activation of focal adhesion kinases", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 313, no. 3, 16 January 2004 (2004-01-16), pages 534 - 540, XP004481590, ISSN: 0006-291X *
KIM J-S ET AL: "Inhibition of angiogenesis and angiogenesis-dependent tumor growth by the cryptic kringle fragments of human apolipoprotein(a)", JOURNAL OF BIOLOGICAL CHEMISTRY 01 AUG 2003 UNITED STATES, vol. 278, no. 31, 1 August 2003 (2003-08-01), pages 29000 - 29008, XP002450345, ISSN: 0021-9258 *
See also references of WO2004073730A1 *
XUE S ET AL: "Apo(a) kringle V inhibits endothelial cell proliferation", FIBRINOLYSIS AND PROTEOLYSIS, vol. 14, no. Supplement 1, June 2000 (2000-06-01), & XVTH INTERNATIONAL CONGRESS ON FIBRINOLYSIS AND PROTEOLYSIS; HAMAMATSU, JAPAN; JUNE 25-29, 2000, pages 35, XP008083595, ISSN: 1369-0191 *
YU H-K ET AL: "Suppression of colorectal cancer liver metastasis and extension of survival by expression of apolipoprotein(a) kringles", CANCER RESEARCH 01 OCT 2004 UNITED STATES, vol. 64, no. 19, 1 October 2004 (2004-10-01), pages 7092 - 7098, XP002450346, ISSN: 0008-5472 *

Also Published As

Publication number Publication date
WO2004073730A1 (en) 2004-09-02
AU2004212856A1 (en) 2004-09-02
JP2006518342A (ja) 2006-08-10
AU2004212856B2 (en) 2007-07-19
CA2516172A1 (en) 2004-09-02
KR20040075270A (ko) 2004-08-27
KR100595364B1 (ko) 2006-07-03
EP1608395A1 (de) 2005-12-28
BRPI0407611A (pt) 2006-02-14
CN1753685A (zh) 2006-03-29
CN100546646C (zh) 2009-10-07
RU2306147C2 (ru) 2007-09-20
RU2005129273A (ru) 2006-03-10

Similar Documents

Publication Publication Date Title
HUS2200020I1 (hu) Aktív vegyületeket tartalmazó fungicid kombinációk
EP1631239A4 (de) Pharmazeutische zusammensetzungen mit aktiven vitamin-d-verbindungen
PL374390A1 (en) Fungicidal active substance combinations
EP1622540A4 (de) Formulierungen für zellen-plan-abhängige krebsmittel
ZA200604352B (en) Azepinondole derivatives as pharmaceutical agents
PL372084A1 (en) 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient
GB0323908D0 (en) Pharmaceutical foam formulation
HUP0501186A2 (en) Pharmaceutical compositions comprising active vitamin d compounds
IL173808A0 (en) Pharmaceutical liposomal formulations
IL157741A0 (en) Pharmaceutical compositions containing an antihyperplastic active agent
IL172824A0 (en) Pharmaceutical formulations
IL164699A0 (en) Diketohydrazine derivative compounds and drugs containing the compounds as the active ingredient
GB0302671D0 (en) Pharmaceutical formulations
EP1608395A4 (de) Antikrebsmittel mit lk8-protein als wirkstoff
HK1090546A1 (en) Dosage form containing pantoprazole as active ingredient
HK1105202A1 (en) Heterocyclic compound and anti-malignant-tumor agent containing the same as active ingredient
IL174135A0 (en) Benzimidazole acetonitrile derivatives, their preparation and and pharmaceutical compositions containing them
GB0316206D0 (en) Pharmaceutical formulation
GB0318448D0 (en) Formulation
GB0302672D0 (en) Pharmaceutical formulations
GB0312195D0 (en) Formulation
GB0316341D0 (en) Pharmaceutical formulations
GB0320522D0 (en) Formulation
GB0326221D0 (en) Therapeutic agents,compositions,preparations and uses
AU2003259532A1 (en) Ready-to-drink formulation containing an active ingredient

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050919

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20070919BHEP

Ipc: A61P 35/04 20060101ALI20070919BHEP

Ipc: A61K 38/17 20060101AFI20070919BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20071002

17Q First examination report despatched

Effective date: 20100730

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130903